[4] Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007; 119...
FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
FASENRA® (benralizumab) is an add-on maintenance treatment for patients 6 and older who are diagnosed with severe eosinophilic asthma.
In SIROCCO (48 weeks) and CALIMA (56 weeks), asthma exacerbation was defined as a worsening of asthma that led to use of systemic corticosteroids for ≥3 days, temporary increase in a stable OCS background dose for ≥3 days, emergency/urgent care visit because of asthma that needed sys...
此外，接受Fasenra治疗的患者在第48至52周期间能够完全逐渐减少口服皮质类固醇的比例较高。参考来源：‘FASENRA approved for treatment of children aged 6 to 11 with severe asthma’，新闻稿。AstraZeneca；2024年4月11日发布。注：本文旨在介绍医药健康研究，不作任何用药依据，具体用药指引，请咨询主治医师。
April 5, 2024 - The FDA approved AstraZeneca’s Fasenra (benralizumab), as add-on maintenance treatment of patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype.Download PDFReturn to publicationsQuick links Clinical publications Contact us Drug recalls-...
FASENRA is an add-on maintenance treatment for patients 6 and older with severe eosinophilic asthma.See more. Not for sudden breathing problems. This Site is for US Patients Select condition: Eosinophilic Asthma Approved use Patient Information ...
Asthmais a long-term (chronic) condition of the lungs that can make it hard to breathe. The airways can get narrowed fromswelling (inflammation)and because the muscles in the airways tighten up. This swelling and tightness can make the airways very irritated and sensitive. The airways can als...
哮喘(asthma)是最常见的慢性儿童疾病,可引起咳嗽、喘息和呼吸困难等严重症状。患有严重哮喘的儿童及其家人面临着沉重的负担,包括学业成绩受损、医疗资源使用量大幅增加以及生活质量较差。严重哮喘是一种使人衰弱的哮喘,治疗起来可能很复杂且具有挑战性。
此外,接受Fasenra治疗的患者在第48至52周期间能够完全逐渐减少口服皮质类固醇的比例较高。 参考来源:‘FASENRA approved for treatment of children aged 6 to 11 with severe asthma’,新闻稿。AstraZeneca;2024年4月11日发布。 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。